The landscape of cancer treatment in India is undergoing a transformation with the introduction of affordable Chinese immunotherapy drugs. Vijay Patil, a cancer specialist at PD Hinduja Hospital in Mumbai, has successfully treated patients with lower-cost alternatives that have shown strong clinical responses. These therapies, developed in China and marketed through partnerships with Indian companies, are filling a critical gap left by the high prices of Western immunotherapy drugs, which can cost between ₹1 lakh ($1,200 USD) to ₹5 lakh ($6,000 USD) per session.

A study published in The Lancet indicates that 34-84% of cancer patients in India face catastrophic expenditure on treatment, making affordable options vital. Doctors like Sunil Chopade from Jaslok Hospital advocate for the adoption of effective Chinese immunotherapy molecules, which are now approved for various cancers in India. The cost of these treatments is around ₹50,000 ($600 USD) per session, significantly lower than Western counterparts, allowing for better patient adherence to long-term care.

Indian pharmaceutical companies are capitalizing on this trend. For instance, Intas Pharma and Glenmark have launched drugs licensed from Chinese firms, offering hope for patients who previously struggled with financial toxicity. Experts predict that within a decade, Chinese medicines will increasingly replace those from the US and Europe in the Indian market, driven by their affordability and efficacy.